| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Health Care sector is very positive (overall 1.8, positive 2.7, negative -1) on 20251104. The forces of Price Level (2), Sentiment towards Fundamentals (1.9), Option Speculation (1.5), and Sector Price Trend (-0.4) will drive up the price. The forces of Broad Market Trend (-0.5), Valuation Sentiment (-1), and Market Risk Prefrence (0) will drive down the price. 'Buy the dips' is the preferred trading strategy. Hourly SMA 20 trend line is likely to provide a support from any pullbacks. The swing to upside will be significant considering the high positive sentiment forces (2.7). The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Market Sentiment | Trend Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-04 | 3% | 1.9% | 145.01 | 65 | 0.42% | 0% | 0.6 | -0.1 | 1.9 | 4.4 |
| 2025-11-03 | 2% | 1.7% | 144.41 | 54 | 0.12% | 0% | 0.3 | -0.5 | 1.7 | 2.7 |
| 2025-11-02 | 1% | 1.6% | 1.2 | -0.3 | 1.8 | 0 | ||||
| 2025-11-01 | 1% | 1.6% | 1.1 | -0.3 | 1.7 | 1.5 | ||||
| 2025-10-31 | 2% | 1.4% | 144.23 | 51 | -0.05% | 0.07% | 1.1 | -0.3 | 1.7 | 3.5 |
| 2025-10-30 | 3% | 1.3% | 144.3 | 52 | 0.17% | 0.14% | 1.1 | -0.4 | 2 | 4.9 |
| 2025-10-29 | 1% | 1% | 144.05 | 47 | -0.95% | 0.07% | 1.7 | -0.4 | 2.1 | -0.9 |
| 2025-10-28 | 2% | 1% | 145.44 | 74 | -0.65% | 0.21% | 1.8 | 0.2 | 2 | 5.2 |
| 2025-10-27 | 1% | 1% | 146.38 | 87 | 0.23% | 0.35% | 1.5 | 0.3 | 1.9 | 2.9 |
| 2025-10-26 | 1% | 1% | 1.3 | 0.4 | 2 | 1 | ||||
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| 1 (8) Obesity drugs may be sold at just $149 a month, get covered under Medicare under a reported White House deal in the works The White House is close to announcing a deal with drugmakers Eli Lilly and Novo Nordisk that would cut the price of obesity drugs to $149 per month in some cases and extend coverage to certain Medicare and Medicaid beneficiaries, according to media reports Tuesday. (https://www.marketwatch.com/) Tue. Nov 4, 2025 | |
| 2 (6) These Stocks Could Be Catalysts for CURE Glossed-over corners of the market have a way of rebounding before many investors notice, indicating risk-tolerant traders may want to remain mindful of the Direxion Daily Healthcare Bull 3X ETF (CURE). (https://www.etftrends.com/) Tue. Nov 4, 2025 | |
| 3 (7) Masimo Corporation Bottom Line Rises In Q3 Masimo Corporation (MASI) announced a profit for its third quarter that Increases, from the same period last year The company's earnings came in at $53.7 million, or $0. (https://www.rttnews.com/) Tue. Nov 4, 2025 | |
| 4 (8) Amgen Lifts Outlook Again After Drug Sales Beat Expectations Amgen Inc. raised its full-year guidance after third-quarter results beat expectations, a positive sign in light of hurdles from Washington and the risks of increased competition. (https://www.bloomberg.com/) Tue. Nov 4, 2025 | |
| 5 (7) Wall Street gets another reason to like Eli Lilly stock, and DuPont's spin is going to plan Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading. (https://www.cnbc.com/) Tue. Nov 4, 2025 | |
| 6 (-6) Analysts Lower Cigna Targets As PBM Segment Guidance Surprises Market Cigna expects 2026–2027 margin pressure from its new rebate-free PBM model as major clients renew at lower margins, prompting analyst target cuts. (https://www.benzinga.com/) Tue. Nov 4, 2025 | |
| 7 (5) Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escalating takeover fight. (https://www.benzinga.com/) Tue. Nov 4, 2025 | |
| 8 (6) Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House Eli Lilly and Company (NYSE:LLY) shares are trading slightly lower on Tuesday after its previous gains following reports indicating the company is close to finalizing a White House agreement to provide its lowest-dose obesity medications at $149 per month, which could open the door to Medicare coverage and broader reimbursement options. (https://www.benzinga.com/) Tue. Nov 4, 2025 | |
| 9 (-6) Pfizer is losing its fight with Novo Nordisk to get back in the obesity-drug game Pfizer’s buyout bid for Metsera was deemed inferior to the latest bid from Novo Nordisk, putting the original agreement in doubt despite legal efforts to enforce it. (https://www.marketwatch.com/) Tue. Nov 4, 2025 | |
| 10 (-5) Pfizer plays hardball in weight-loss drug fight Pfizer has filed two lawsuits to block Novo Nordisk’s $9bn bid to buy Metsera (https://www.ft.com/) Tue. Nov 4, 2025 | |
| 11 (8) Lilly and Novo Rise on Report of Deal for Medicare Coverage Shares of Eli Lilly & Co and Novo Nordisk A/S rose on a report that the companies were preparing to announce new deals with the White House to lower prices for weight-loss drugs in exchange for coverage under Medicare. (https://www.bloomberg.com/) Tue. Nov 4, 2025 | |
| 12 (5) Metsera says Novo Nordisk’s new up to $10 billion bid for obesity drugmaker is ‘superior’ to revised Pfizer offer The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in. (https://www.cnbc.com/) Tue. Nov 4, 2025 | |
| 13 (7) HIMS CEO Says 'A Little Bit of Craziness' Is The Secret To Building A Global Health Platform Hims & Hers Health (HIMS) CEO Andrew Dudum, sees potential for emotional and medical transformation and plans for global expansion. (https://www.benzinga.com/) Tue. Nov 4, 2025 | |
| 14 (5) Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera. Metsera said Tuesday that Novo is now offering to pay as much as $10 billion for Metsera. Metsera said Pfizer also has changed an offer it made in September of nearly $4.9 billion it to provide more cash up front. (https://finance.yahoo.com/) Tue. Nov 4, 2025 | |
| 15 (5) Pfizer’s revenue falls as COVID sales and vaccine recommendations continue to fade Pfizer’s stock rises as quarterly profit beat profit expectations and the full-year outlook was raised. (https://www.marketwatch.com/) Tue. Nov 4, 2025 | |
| 16 (6) Pfizer Boosts Profit View as It Battles for Obesity Startup Pfizer Inc. raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales growth that’s driving its battle for the obesity start up Metsera Inc. (https://www.bloomberg.com/) Tue. Nov 4, 2025 | |
| 17 (7) Top 3 Health Care Stocks Which Could Rescue Your Portfolio In November (https://www.benzinga.com/) Tue. Nov 4, 2025 | |
| 18 (7) Philips Navigates Tariffs Through Cost Discipline, Reaffirms Outlook Philips Q3 earnings topped forecasts as sales rose 3% and margins improved, supported by cost savings and steady North American demand. (https://www.benzinga.com/) Tue. Nov 4, 2025 | |
| 19 (5) Is Eli Lilly a Millionaire Maker? Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider. (https://www.fool.com/) Tue. Nov 4, 2025 | |
| 20 (2) Earnings from Uber, Shopify, Spotify and Pfizer: Market Movers Uber (UBER) posted its strongest quarterly growth since late 2023 as customers ordered more rides and deliveries than expected. However, its share price fell in the premarket as its forecasts underwhelmed investors. Meanwhile Spotify's (SPOT) share price rose before the opening bell after the world's largest streaming service reported stronger-than-expected third-quarter results. Other results this morning include Shopify (SHOP) and pharmaceutical giant, Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance. (https://finance.yahoo.com/) Tue. Nov 4, 2025 | |
| 21 (2) $134M in Insider Moves: What It Might Mean for KMI, ISRG and QS Are Intuitive Surgical insiders cashing out after its October earnings surge? See the signals insiders are sending at KMI, ISRG, and QuantumScape. (https://www.marketbeat.com/) Mon. Nov 3, 2025 | |
| 22 (-7) Major diabetes health care company files Chapter 11 bankruptcy The healthcare technology company, which provides services to high-risk diabetes patients, files for bankruptcy protection (https://www.thestreet.com/) Mon. Nov 3, 2025 | |
| 23 (8) The Ensign Group, Inc. Q3 Profit Increases, Beats Estimates The Ensign Group, Inc. (ENSG) released earnings for its third quarter that Increased from last year and beat the Street estimates. The company's earnings came in at $83. (https://www.rttnews.com/) Mon. Nov 3, 2025 | |
| 24 (1) Inspire Medical Systems, Inc. Q3 Profit Decreases, But Beats Estimates Inspire Medical Systems, Inc. (INSP) announced earnings for third quarter that Decreased from last year but beat the Street estimates. The company's earnings came in at $9. (https://www.rttnews.com/) Mon. Nov 3, 2025 | |
| 25 (0) Pediatrix Medical Group Inc. Complete Pediatrix Medical Group Inc. stock information by Barron's. View real-time MD stock price and news, along with industry-best analysis. (https://www.barrons.com/) Mon. Nov 3, 2025 | |
| 26 (7) Hims Shares Rise on Talks to Offer Novo’s New Obesity Pill Hims & Hers Health Inc. rose in late trading after the telehealth company said it was in talks with Novo Nordisk A/S to make its new obesity pill available on the company’s site. (https://www.bloomberg.com/) Mon. Nov 3, 2025 | |
| 27 (7) Hims & Hers Stock Pops After Q3 Earnings: Here's Why Here's a look at the Q3 earnings report from Hims & Hers Health. (https://www.benzinga.com/) Mon. Nov 3, 2025 | |
| 28 (7) Cigna Group stock outperforms competitors on strong trading day Shares of Cigna Group CI rallied 5.81% to $258.62 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.17% to 6,851.97 and the Dow Jones Industrial Average DJIA falling 0.48% to 47,336.68. The stock's rise snapped a four-day losing streak. (https://www.marketwatch.com/) Mon. Nov 3, 2025 | |
| 29 (8) IDEXX Laboratories Inc. stock outperforms competitors on strong trading day Shares of IDEXX Laboratories Inc. IDXX jumped 14.84% to $722.94 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.17% to 6,851.97 and the Dow Jones Industrial Average DJIA falling 0.48% to 47,336.68. This was the stock's third consecutive day of gains. (https://www.marketwatch.com/) Mon. Nov 3, 2025 | |
| 30 (7) Is UnitedHealth an Undervalued Stock to Buy Now? UnitedHealth is looking forward to the next calendar year when it can raise prices on an important customer segment. (https://www.fool.com/) Mon. Nov 3, 2025 | |
| 31 (-6) Pfizer files second lawsuit to block Novo Nordisk’s $9bn Metsera bid Pfizer has filed a second lawsuit against Novo Nordisk and obesity drug start-up Metsera, redoubling its fight to stop Novo’s bid for the biotech... (https://finance.yahoo.com/) Mon. Nov 3, 2025 | |
| 32 (-5) Kimberly-Clark Buys Embattled Tylenol Maker Kenvue In $48 Billion Deal President Donald Trump has claimed Kenvue’s pain reliever is a potential cause of autism, despite clear evidence. (https://www.forbes.com/) Mon. Nov 3, 2025 | |
| 33 (-5) Pfizer Sues Novo, Metsera for Second Time in Brewing Deal War Pfizer Inc. accused Novo Nordisk A/S of trying to stifle competition in the weight-loss market by attempting to acquire obesity startup Metsera Inc., the second lawsuit in four days as Pfizer tries to retain its grip on a deal that Novo upended last week. (https://www.bloomberg.com/) Mon. Nov 3, 2025 | |
| 34 (8) Idexx Laboratories Extends Rally Following Upbeat Q3 Earnings, Outlook Idexx stock gains after Q3 earnings and revenue beat expectations, driven by strong CAG growth and raised 2025 earnings and sales guidance. (https://www.benzinga.com/) Mon. Nov 3, 2025 | |
| 35 (8) Kenvue jumps 22% on $48.7 billion Kimberly-Clark merger deal Kenvue jumps 22% on $48.7 billion Kimberly-Clark merger deal (https://www.investing.com/) Mon. Nov 3, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA